

Cancer-related thrombosis: impact of biological sex on the risk of rethrombosis and bleeding

Silvia García Adrián,^{1,2} Claudia Iglesias Pérez,³ Alberto Carmona-Bayonas,⁴ Laura Ortega Morán,^{1,2} Jaime Rubio Pérez,^{2,5} Purificación Martínez del Prado,^{2,6} Eva Martínez de Castro,^{2,7} Fernando Neria,⁸ Isaura Fernández Pérez,^{2,9} Marta García de Herreros,¹⁰ Marta Carmona Campos,^{2,11} Ignacio García Escobar,^{2,12} Rut Porta Balanyà,^{2,13} David Marrupe González,^{2,8,14} Paula Jiménez Fonseca,³ María Esperanza Guirao García,⁴ Manuel Sánchez Cánovas,^{2,4} José Muñoz Langa,^{2,15} Pedro Pérez Segura,^{2,16} M^a José Méndez Vidal^{2,17} and Andrés J. Muñoz Martín^{1,2}

¹Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid;

²Thrombosis and Cancer Section of the Spanish Society of Medical Oncology (SEOM), Madrid; ³Medical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Universidad de Oviedo, Oviedo; ⁴Medical Oncology Department, Hospital Universitario Morales Meseguer, University of Murcia, IMIB, Murcia; ⁵Medical Oncology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid; ⁶Medical Oncology Department, Hospital de Basurto, Bilbao; ⁷Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander; ⁸Facultad de Medicina, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Madrid; ⁹Medical Oncology Department, Complejo Hospitalario Universitario de Vigo, Vigo; ¹⁰Medical Oncology Department, Hospital Clinic de Barcelona, Barcelona; ¹¹Medical Oncology Department, Complejo Hospitalario Universitario de Santiago, Santiago Compostela; ¹²Medical Oncology Department, Hospital Universitario de Toledo, Toledo; ¹³Medical Oncology Department, Hospital Universitari Dr Josep Trueta, Institut Català d'Oncologia, Girona; ¹⁴Medical Oncology Department, Hospital Universitario de Móstoles, Móstoles; ¹⁵Medical Oncology Department, Hospital Arnau de Vilanova de Valencia, Valencia; ¹⁶Medical Oncology Department, Hospital Universitario Clínico San Carlos, Madrid and ¹⁷Medical Oncology Department, Hospital Universitario Reina Sofía de Córdoba, Córdoba, Spain

Correspondence: S. García Adrián
silvia_g_adrian@hotmail.com

Received: July 1, 2024.
Accepted: December 5, 2024.
Early view: December 12, 2024.

<https://doi.org/10.3324/haematol.2024.286152>

©2025 Ferrata Storti Foundation
Published under a CC BY-NC license



Table S1. Univariate analysis and multivariate analysis adjusted for risk of rethrombosis (Fine-Gray proportional subdistributions hazards model)

	At 6 months of follow up				At the end of follow up			
	Univariate		Adjusted multivariate		Univariate		Adjusted multivariate	
	sHR (95% CI)	p-value	sHR (95% CI)	p-value	sHR (95% CI)	p-value	sHR (95% CI)	p-value
Male sex	1.17 (0.68-2.02)	0.57			1.25 (0.93-1.67)	0.14	1.22 (0.90-1.67)	0.20
Age > 70 years	0.48 (0.24-0.96)	0.039	0.45 (0.23-0.91)	0.025	0.82 (0.60-1.13)	0.23		
TNM stage								
Stage I-III	---				---			
Stage IV	0.82 (0.46-1.47)	0.51			1.03 (0.75-1.42)	0.86		
Tumor location								
Other	---		---		---		---	
Lung	1.47 (0.60-3.59)	0.40	1.52 (0.62-3.72)	0.36	1.52 (0.93-2.49)	0.097	1.46 (0.90-2.35)	0.13
Urological	1.06 (0.52-2.23)	0.94	1.21 (0.32-4.55)	0.78	1.08 (0.52-2.23)	0.84	0.99 (0.48-2.03)	0.98
Breast	0.78 (0.21-2.91)	0.71	0.79 (0.21-2.96)	0.72	1.41 (0.79-2.56)	0.26	1.53 (0.82-2.84)	0.18
Digestive	1.82 (0.82-4.00)	0.14	1.99 (0.90-4.44)	0.088	1.87 (1.21-2.89)	0.005	1.80 (1.16-2.77)	0.008
Initial VTE								
Unsuspected	---				---			
Suspected	1.24 (0.72, 2.15)	0.43			0.87 (0.65, 1.17)	0.35		

sHR: Sub-distribution Hazard Ratio. CI: Confidence Interval.

Table S2. Univariate analysis and multivariate analysis adjusted for risk of major bleeding (Fine-Gray proportional subdistributions hazards model)

	At 6 months of follow up				At the end of follow up			
	Univariate		Adjusted multivariate		Univariate		Adjusted multivariate	
	sHR (95% CI)	p-value	sHR (95% CI)	p-value	sHR (95% CI)	p-value	sHR (95% CI)	p-value
Male sex	1.95 (0.92-4.13)	0.083	1.85 (0.87-3.94)	0.11	1.73 (1.08-2.75)	0.022	2.34 (1.36-4.04)	0.002
Kidney function								
Glomerular filtration ≥ 60 ml/ min	----				----			
Glomerular filtration 30- 59 ml/ min	1.45 (0.55-3.78)	0.45			1.30 (0.68-2.46)	0.43		
Glomerular filtration < 30 ml/ min	0				0			
Age > 70 years	0.70 (0.32-1.57)	0.39			0.82 (0.50-1.34)	0.43		
Active tumor disease	2.59 (0.62-10.9)	0.19			1.85 (0.85-4.0)	0.12		
TNM stage								
Stage I-III	----				----			
Stage IV	0.98 (0.46-2.13)	0.96			1.06 (0.64-1.75)	0.81		
Bleeding risk	3.33 (1.57-7.08)	0.002	2.08 (0.88-4.90)	0.094	4.08 (2.57-6.49)	<0.001	3.45 (2.05-5.80)	<0.001
Active bleeding cancer	7.07 (2.70-18.5)	<0.001	4.08 (1.37-12.2)	0.012	5.08 (2.49-10.54)	<0.001	2.32 (1.04-5.21)	0.041
Tumor location								
Other	----				----		----	
Lung	0.77 (0.21-2.85)	0.69			0.54 (0.24-1.21)	0.14	0.46 (0.20-1.09)	0.078
Urological	1.13 (0.22-5.81)	0.89			0.88 (0.32-2.39)	0.8	0.58 (0.21-1.62)	0.3
Breast	1.24 (0.30-5.19)	0.77			1.42 (0.66-3.04)	0.37	2.75 (1.18-6.38)	0.019
Digestive	1.88 (0.70-5.10)	0.21			1.23 (0.68-2.21)	0.49	1.04 (0.56-1.91)	0.91
Platelets < 100000 counts/ µl	1.54 (0.47-5.03)	0.48			1.18 (0.51-2.71)	0.70		
Antiangiogenic Therapy	1.59 (0.48-5.22)	0.45			1.00 (0.41-2.48)	> 0.999		

sHR: Sub-distribution Hazard Ratio. CI: Confidence Interval.

Table S3. Univariate analysis and multivariate analysis adjusted for risk of rethrombosis (Cox proportional hazards model)

	At 6 months of follow up				At the end of follow up			
	Univariate		Adjusted multivariate		Univariate		Adjusted multivariate	
	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
Male sex	1.64 (1.07-2.50)	0.023			1.33 (0.99-1.78)	0.059	1.2 (0.87-1.66)	0.264
Age > 70 years	0.65 (0.40-1.05)	0.078	0.6 (0.37-0.98)	0.039	0.86 (0.63-1.19)	0.377		
TNM stage								
Stage I-III	---				---		---	
Stage IV	1.35 (0.85-2.16)	0.204			1.56 (1.13-2.16)	0.008	1.49 (1.07-2.07)	0.019
Tumor location								
Other	---		---		---		---	
Lung	1.90 (0.93-3.86)	0.076	1.96 (0.97-3.99)	0.062	1.84 (1.12-3.01)	0.016	1.65 (1.01-2.74)	0.047
Urological	1.19 (0.42-3.39)	0.74	1.36 (0.48-3.88)	0.562	1.11 (0.54-2.30)	0.778	0.95 (0.45-1.99)	0.885
Breast	0.65 (0.21-2.00)	0.448	0.65 (0.21-2.01)	0.451	1.08 (0.59-1.97))	0.808	1.21 (0.65-2.24)	0.550
Digestive	2.36 (1.26-4.44)	0.007	2.68 (1.42-5.06)	0.002	1.86 (1.20-2.88)	0.005	1.74 (1.11-2.70)	0.015
Initial VTE								
Unsuspected	---				---			
Suspected	1.39 (0.92, 2.10)	0.117	1.51 (0.99-2.28)	0.054	0.93 (0.70-1.25)	0.638		

HR: Hazard Ratio. CI: Confidence Interval.

Table S4. Univariate analysis and multivariate analysis adjusted for risk of major bleeding (Cox proportional hazards model)

	At 6 months of follow up				At the end of follow up			
	Univariate		Adjusted multivariate		Univariate		Adjusted multivariate	
	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
Male sex	2.31 (1.29-4.13)	0.005	2.14 (1.17-3.90)	0.014	1.81 (1.13-2.89)	0.013	2.32 (1.31-4.11)	0.004
Kidney function								
Glomerular filtration $\geq$ 60 ml/ min	----				----			
Glomerular filtration 30- 59 ml/ min	1.36 (0.64-2.88)	0.429			1.35 (0.71-2.56)	0.359		
Glomerular filtration < 30 ml/ min	0				0			
Age > 70 years	0.77 (0.42-1.39)	0.384			0.86 (0.53-1.42)	0.564		
Active tumor disease	3.36 (1.05-10.8)	0.041	2.52 (0.78-8.15)	0.124	2.48(1.13-5.42)	0.023	2.00 (0.90-4.44)	0.089
TNM stage								
Stage I-III	----				----			
Stage IV	1.08 (0.60-1.94)	0.79			1.42 (0.86-2.36)	0.175		
Bleeding risk	4.21 (2.43-7.29)	<0.001	2.31 (1.17-4.56)	0.016	4.69 (2.94-7.48)	<0.001	3.41 (1.97-5.89)	<0.001
Active bleeding cancer	8.02 (3.9-16.4)	<0.001	3.58 (1.47-8.71)	0.005	6.3 (3.13-12.7)	<0.001	2.42 (1.05-5.54)	0.037
Tumor location								
Other	----				----			
Lung	0.82 (0.32-2.07)	0.667			0.61 (0.27-1.38)	0.237	0.41 (0.17-1.01)	0.052
Urological	1.15 (0.36-3.68)	0.810			0.90 (0.33-2.46)	0.836	0.56 (0.20-1.56)	0.264
Breast	1.21 (0.44-3.32)	0.718			1.16 (0.54-2.51)	0.703	2.23 (0.96-5.21)	0.062
Digestive	1.50 (0.73-3.10)	0.273			1.24 (0.69-2.23)	0.477	0.97 (0.53-1.78)	0.923
Platelets< 100000 counts/ μ l	1.9 (0.81-4.44)	0.138			1.31 (0.57-3.02)	0.524		
Antiangiogenic Therapy	0.85 (0.26-2.71)	0.779			1.04 (0.42-2.57)	0.939		

HR: Hazard Ratio. CI: Confidence Interval.